Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.83 | N/A | -200.99% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.83 | N/A | -200.99% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current financial performance but remains committed to their long-term goals. They did not provide specific guidance for the upcoming quarters.
Management acknowledged the challenges faced this quarter.
They emphasized a focus on long-term strategies despite current setbacks.
The earnings report indicates that Soleno Therapeutics is facing significant challenges, particularly reflected in the EPS miss. Despite this, the stock saw a slight increase of 0.83%, which may suggest that investors are optimistic about the company's long-term strategy. The lack of revenue data and guidance leaves uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
VERTEX PHARMACEUTICA
Nov 4, 2024